Abstract:Abstract Changes to lipid metabolism are tightly associated with the onset and pathology of Alzheimer’s disease (AD). Lipids are complex molecules comprising many isomeric and isobaric species, necessitating detailed analysis to enable interpretation of biological significance. Our expanded targeted lipidomics platform (569 species across 32 classes) allows for detailed lipid separation and characterisation. In this study we examined peripheral samples of two cohorts (AIBL, n = 1112 and ADNI, n = 800). We are able to identify concordant peripheral signatures associated with prevalent AD arising from lipid pathways including; ether lipids, sphingolipids (notably GM 3 gangliosides) and lipid classes previously associated with cardiometabolic disease (phosphatidylethanolamine and triglycerides). We subsequently identified similar lipid signatures in both cohorts with future disease. Lastly, we developed multivariate lipid models that improved classification and prediction. Our results provide a holistic view between the lipidome and AD using a comprehensive approach, providing targets for further mechanistic investigation.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is the relationship between Alzheimer's disease (AD) and lipid metabolism. Specifically, the study aims to identify peripheral lipid characteristics related to AD through detailed lipidomics analysis and explore whether these lipid characteristics can predict the risk of AD before the onset of the disease. The study used data from two large - scale clinical research cohorts (AIBL and ADNI) to improve the universality and reliability of the results. ### Research Background Alzheimer's disease is a neurodegenerative disease, manifested as a gradual decline in cognitive function, usually with memory loss as the first symptom. With the aging of the global population, it is expected that the number of AD patients worldwide will reach 81 million by 2040. In recent years, the failure of many AD clinical trials has prompted researchers to rethink the research methods of AD and recognize that in addition to the known pathological mechanisms, there are other potential pathogenic mechanisms. Alterations in lipid metabolism have been proven to be related to AD. Therefore, in - depth understanding of the role of lipid metabolism pathways in AD may provide clues for finding new therapeutic targets. ### Research Objectives 1. **Characterize the Lipidome in Detail**: Use an extended targeted lipidomics platform to detect 569 lipid species in 32 classes of lipids to obtain more detailed lipidome data. 2. **Identify Lipid Characteristics Related to AD**: Identify lipid characteristics related to AD by analyzing peripheral samples from two large - scale clinical research cohorts (AIBL and ADNI). 3. **Predict the Risk of Future AD**: Develop a multivariate lipid model to improve the classification and prediction ability of AD. ### Main Findings - **Consistency of Lipid Characteristics**: In two independent cohorts, the researchers found some consistent peripheral lipid characteristics that are closely related to the occurrence and development of AD. In particular, ether lipids, sphingolipids (especially GM3 gangliosides), and phosphatidylethanolamine and triglycerides related to cardiometabolic diseases. - **Prediction of Future AD**: Through multivariate modeling, the researchers found that adding specific lipid species can significantly improve the classification and prediction ability of AD. For example, in the AIBL cohort, after adding 10 lipid species, the C - statistic increased from 0.731 to 0.752, and the NRI was 0.40; in the ADNI cohort, the C - statistic increased from 0.820 to 0.869, and the NRI was 0.84. ### Conclusion This study, through detailed lipidomics analysis, revealed peripheral lipid characteristics related to AD and developed a multivariate lipid model that can improve the classification and prediction ability of AD. These findings provide a new perspective for understanding the pathological mechanism of AD and potential targets for future diagnosis and treatment strategies.

Concordant peripheral lipidome signatures in two large clinical studies of Alzheimer’s disease

Serum Metabolites Differentiate Amnestic Mild Cognitive Impairment From Healthy Controls And Predict Early Alzheimer'S Disease Via Untargeted Lipidomics Analysis

Pathway-based integration of multi-omics data reveals lipidomics alterations validated in an Alzheimer's disease mouse model and risk loci carriers

Lipid Profiling of Alzheimer’s Disease Brain Highlights Enrichment in Glycerol(phospho)lipid, and Sphingolipid Metabolism

Sets of coregulated serum lipids are associated with Alzheimer's disease pathophysiology

Quantitative Lipidomic Analysis of Serum Phospholipids Reveals Dissociable Markers of Alzheimer's Disease and Subcortical Cerebrovascular Disease.

Multi-Omic analyses characterize the ceramide/sphingomyelin pathway as a therapeutic target in Alzheimer's disease

Lipidomics of Alzheimer's disease: current status

Transcriptomic Analysis of Lipid Metabolism Genes in Alzheimer's Disease: Highlighting Pathological Outcomes and Compartmentalized Immune Status

Integrative Metabolomics-Genomics Approach Reveals Key Metabolic Pathways and Regulators of Alzheimer's Disease

Multi-omic ADNI CSF and plasma data integration identifies distinct metabolic transitions in disease progression in Alzheimer's Disease

Identification of Abnormal Lipid Profiles Promote Cognitive Decline in Alzheimer's Disease Spectrum Via Large-Scale Brain Connectivity

Blood-based metabolic signatures in Alzheimer's disease

Large-scale proteomic analysis of Alzheimer’s disease brain and cerebrospinal fluid reveals early changes in energy metabolism associated with microglia and astrocyte activation

Mass spectrometry imaging highlights dynamic patterns of lipid co‐expression with Aβ plaques in mouse and human brains

New insights in lipid metabolism: potential therapeutic targets for the treatment of Alzheimer's disease

Plasma Lipoproteome in Alzheimer’s Disease: a Proof-of-concept Study

Metabolomic and lipidomic signatures in autosomal dominant and late-onset Alzheimer's disease brains

Identifying Differences in Bile Acid Pathways for Cholesterol Clearance in Alzheimer’s Disease Using Metabolic Networks of Human Brain Regions

Untargeted Lipidomics Reveals Progression of Early Alzheimer’s Disease in APP/PS1 Transgenic Mice

Polygenic Effects of the Lipid Metabolic Pathway Accelerated Pathological Changes and Disrupted Default Mode Network Trajectory Across the Alzheimer’s Disease Spectrum